PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma

Conditions: NK-T-Cell Lymphoma, Extranodal Interventions: Drug: 4 cycles of ESA regimen with sandwiched radiotherapy; Drug: 2 cycles of ESA regimen sequential radiotherapy and 2 cycles of PD-1 monoclonal antibody combined with pegaspargase; Drug: 2 cycles of ESA regimen, 2 cycles of PD-1 monoclonal antibody and concurrent radiotherapy, 2 cycles of PD-1 monoclonal antibody combined with pegaspargase Sponsors: Ruijin Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials